SEC Form SC 13G/A filed

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 [x]            Rule 13d-1(b)

 [  ]            Rule 13d-1(c)

 [  ]            Rule 13d-1(d)

*            The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.  Beneficial ownership information contained herein is given as of the date listed above.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

 

 

 

 

This Amendment No. 3 (the “Amendment”) to Schedule 13G relating to common stock, par value $0.0001 per share (“Common Stock”) of Exela Technologies, Inc., a Delaware corporation (the “Company” or the “Issuer”), is being filed with the Securities and Exchange Commission (the “SEC”) as an amendment to the Schedule 13G filed with the SEC on February 14, 2018, as amended on February 14, 2019 and February 14, 2020.  This Amendment is being filed on behalf of Greenlight Capital, Inc., a Delaware corporation (“Greenlight Inc.”), DME Advisors, LP, a Delaware limited partnership (“DME Advisors”), DME Capital Management, LP, a Delaware limited partnership (“DME CM”), DME Advisors GP, LLC, a Delaware limited liability company (“DME GP” and together with Greenlight Inc., DME Advisors and DME CM, “Greenlight”), and Mr. David Einhorn, the principal of Greenlight (collectively with Greenlight, the “Reporting Persons”).

This Amendment relates to Common Stock of the Issuer held by Greenlight for the account of private investment funds for which Greenlight acts as investment advisor or manages a portfolio (or serves as general partner of the investment advisor or manager of the portfolio) and with respect to which Mr. Einhorn may be deemed to have indirect investment and/or voting power as the principal of Greenlight and other affiliated entities.  DME GP is the general partner of DME Advisors and DME CM.

The filing of this Amendment shall not be construed as an admission that any of the Reporting Persons is for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any of the shares of Common Stock reported herein.  Pursuant to Rule 13d-4, each of the Reporting Persons disclaims all such beneficial ownership except to the extent of its pecuniary interest in any shares of Common Stock, if applicable.

This Amendment is being filed to amend and restate Items 4 and 5 as follows:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Item 5.

Ownership of Five Percent or Less of a Class

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:                February 16, 2021

	GREENLIGHT CAPITAL, INC.
	By: /s/ DANIEL ROITMAN
	Daniel Roitman Chief Operating Officer
	DME ADVISORS, LP By: DME Advisors GP, LLC, its General Partner
	By: /s/ DANIEL ROITMAN
	Daniel Roitman          Chief Operating Officer
	DME CAPITAL MANAGEMENT, LP
	By: DME Advisors GP, LLC,
	its General Partner
	By: /s/ DANIEL ROITMAN
	Daniel Roitman Chief Operating Officer
	DME ADVISORS GP, LLC
	By: /s/ DANIEL ROITMAN
	Daniel Roitman Chief Operating Officer
	/s/ DANIEL ROITMAN*
	Daniel Roitman, on behalf of David Einhorn